TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11694805

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 microg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (40 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of inhaled salmeterol and oral zafirlukast
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9394056

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Contact with the investigator (Control)
Number of subjects: 60
Study: 8194818

Group type: EXPERIMENTAL
Intervention: DMSO gel 10% applied three times a day (n = 77)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo gel excipient (n = 80)
Number of subjects: 157
Study: 3311442

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE)
Number of subjects: 62000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62000
Study: 31858950

Group type: EXPERIMENTAL
Intervention: Parent-delivered inferencing training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active control condition of daily maths activities
Number of subjects: 100
Study: 29505806

Group type: EXPERIMENTAL
Intervention: Multicomponent community intervention (community mobilisation, social marketing, monitoring of alcohol sales to minors)
Number of subjects: 3545

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 3545
Study: 27400966

Group type: EXPERIMENTAL
Intervention: Nondirective coaching
Number of subjects: 518

Group type: COMPARATOR
Intervention: Directive coaching
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Nondirective coaching for subgroups (income above median, recent quit attempts, alternative therapies)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Waiting up to 4 weeks to start coaching
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Highly addicted or depressed smokers who had never quit more than 30 days
Number of subjects: 518
Study: 24522623

Group type: EXPERIMENTAL
Intervention: Lottery incentive with expected daily value of $1.40 (n=21)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lottery incentive with expected daily value of $2.80 (n=26)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (n=28)
Number of subjects: 75
Study: 22024898

Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation program (12 classes starting 6 weeks after surgery)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Educational booklet provided at hospital discharge (part of the intervention)
Number of subjects: 105
Study: 20068289

Group type: EXPERIMENTAL
Intervention: Vinegar (10 g) during mealtime
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vinegar (10 g) 5 hours before meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium acetate (neutralized salt)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vinegar with monosaccharides
Number of subjects: 10
Study: 19008149

Group type: COMPARATOR
Intervention: BNP guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: MR-proANP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivabradine
Number of subjects: 0

Group type: COMPARATOR
Intervention: n-3 PUFA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telemonitoring support
Number of subjects: 0
Study: 16079784

Group type: EXPERIMENTAL
Intervention: Estimates of k(loss) and EDV(2) using a novel application of a multilinear solution for the two-tissue compartment FDOPA model.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multilinear estimates of EDV(2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: k(loss)
Number of subjects: 0
Study: 12495948

Group type: EXPERIMENTAL
Intervention: Site specific advice from a school travel coordinator
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no site specific advice)
Number of subjects: 21
Study: 10423659

Group type: EXPERIMENTAL
Intervention: Telmisartan (n = 385)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Lisinopril (n = 193)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 578

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 578
Study: 8888660

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1848131

Group type: EXPERIMENTAL
Intervention: Chlorothiazide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6844367

Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg capsule daily)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Diethylpropion (75 mg tablet daily)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Phentermine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Diethylpropion
Number of subjects: 99
Study: 30335676

Group type: EXPERIMENTAL
Intervention: Classroom training program for promoting health literacy
Number of subjects: 171
Study: 27659772

Group type: EXPERIMENTAL
Intervention: Breastfeeding counselling sessions
Number of subjects: 3188

Group type: COMPARATOR
Intervention: Usual health messages (Control)
Number of subjects: 3188

Group type: COMPARATOR
Intervention: Multiple micronutrients (Control)
Number of subjects: 3188
Study: 25895909

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®) at a maintenance dose of 2,000 Japanese allergy units (JAU)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study: 23900032

Group type: EXPERIMENTAL
Intervention: Nonlinguistic cognitive processing treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: English treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bilingual (Spanish-English) treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 59
Study: 21114792

Group type: EXPERIMENTAL
Intervention: Rabeprazole-ER 50 mg
Number of subjects: 2130
Study: 20020622

Group type: EXPERIMENTAL
Intervention: Interleukin-6 level in peritoneal exudate
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Peak value of interleukin-6
Number of subjects: 189
Study: 17298254

Group type: EXPERIMENTAL
Intervention: Hydrocodone
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 177
Study: 12612143

Group type: COMPARATOR
Intervention: SPE chips and spread group (17 g/d SPE)
Number of subjects: 380

Group type: COMPARATOR
Intervention: SPE spread (10 g/d SPE)
Number of subjects: 380

Group type: COMPARATOR
Intervention: SPE chips (7 g/d SPE)
Number of subjects: 380

Group type: COMPARATOR
Intervention: All SPE groups
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 380
Study: 10690834

Group type: EXPERIMENTAL
Intervention: Near confluent laser treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Less dense treatment
Number of subjects: 58
Study: 9062865

Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8400484

Group type: EXPERIMENTAL
Intervention: Normal hearing group (10 subjects)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderately hearing-impaired group (10 subjects)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Profoundly hearing-impaired group (10 subjects)
Number of subjects: 30
Study: 3720569

Group type: EXPERIMENTAL
Intervention: Special intervention (cholesterol lowering dietary advice, behaviour modification for cigarette smoking, stepped care pharmacological approach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special intervention (diuretic use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special intervention (hydrochlorothiazide)
Number of subjects: 0
Study: 30340813

Group type: EXPERIMENTAL
Intervention: Cranberry functional beverage (CFB), 750 ml daily for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cranberry functional beverage (CFB)
Number of subjects: 50
Study: 27362613

Group type: EXPERIMENTAL
Intervention: Lens wear with recovery periods of 0, 30, 60, or 80 minutes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spectacle (no lens)
Number of subjects: 25
Study: 25541817

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 103

Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 103
Study: 22453675

Group type: EXPERIMENTAL
Intervention: Parietex™ ProGrip™ mesh (P group)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Lichtenstein repair with lightweight polypropylene mesh (L group)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Parietex™ ProGrip™ mesh without fixation
Number of subjects: 302
Study: 20400496

Group type: EXPERIMENTAL
Intervention: Meals with 250 to 3000 kcal containing 500 mg of calcium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Meals with lower protein and higher fat content
Number of subjects: 6
Study: 18339798

Group type: EXPERIMENTAL
Intervention: All-extremity semirecumbent exercise machine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Portable metabolic unit
Number of subjects: 18
Study: 15606569

Group type: EXPERIMENTAL
Intervention: Verum needles
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo needles
Number of subjects: 28
Study: 12679604

Group type: EXPERIMENTAL
Intervention: Low-intensity standard exercise modalities, 24 sessions (45 min each) over 8-10 weeks
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Low-intensity standard exercise modalities
Number of subjects: 245
Study: 11041534

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19
Study: 8674787

Group type: EXPERIMENTAL
Intervention: Roxithromycin (ROM) administered for 8 weeks
Number of subjects: 30
Study: 1839759

Group type: EXPERIMENTAL
Intervention: Teicoplanin 15 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Teicoplanin 20 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Teicoplanin 25 mg/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.9% NaCl placebo
Number of subjects: 15
Study: 6636790

Group type: EXPERIMENTAL
Intervention: Inderal 40 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inderal 40 mg (in soldiers with anxiety and high pulse)
Number of subjects: 26
Study: 31447129

Group type: EXPERIMENTAL
Intervention: Intravenous fixed-dose combination (FDC) of ibuprofen 300 mg + acetaminophen 1000 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Ibuprofen 300 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 276
Study: 30126463

Group type: EXPERIMENTAL
Intervention: Mobile fresh fruit and vegetable (F&V) markets plus nutrition education (e.g. campaigns, DVDs, newsletters, recipes, and chef demonstrations)
Number of subjects: 1597

Group type: COMPARATOR
Intervention: Physical activity and stress interventions
Number of subjects: 1597
Study: 26575696

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT3 subgroup)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides farinae (Der.f) drops (SLIT1 and SLIT2 subgroups)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Pharmacotherapy with oral antihistamines
Number of subjects: 500
Study: 25155941

Group type: EXPERIMENTAL
Intervention: Acceptance‐Enhanced Behavior Therapy for Trichotillomania
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AAQ‐TTM
Number of subjects: 90
Study: 21641726

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasally)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 38
Study: 20963638

Group type: EXPERIMENTAL
Intervention: Chemotherapy (ifosfamide, DTIC, and doxorubicin administered in 14-day intervals supported by G-CSF on days 5-13)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Radiotherapy alone (control group)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Chemotherapy (ifosfamide, DTIC, and doxorubicin)
Number of subjects: 59
Study: 17351950

Group type: COMPARATOR
Intervention: Oral gefitinib 250 mg daily (G arm)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vinorelbine 15 mg/m2 as an intravenous infusion on Day 1 and oral gefitinib 250 mg daily on Days 2 through 14 every 2 weeks (GV arm)
Number of subjects: 48
Study: 16278618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: E(2) 0.25 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: E(2) 0.5 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: E(2) 1 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: E(2) 1 mg/NETA 0.25 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: E(2) 1 mg/NETA 0.5 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: E(2) 2 mg/NETA 1 mg
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Active treatment (all E(2) groups)
Number of subjects: 327
Study: 11932567

Group type: EXPERIMENTAL
Intervention: Acustat electro‐membrane microcurrent therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9806695

Group type: COMPARATOR
Intervention: sham-TENS (no electrical current) at the Zusanli (ST36) acupoints
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: nonacupoint-TENS at the shoulders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: dermatomal-TENS at the level of the surgical incision
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: acupoint-TENS at the Zusanli acupoints
Number of subjects: 100
Study: 7620745

Group type: EXPERIMENTAL
Intervention: Morning light treatment (8.00-8.30 a.m., n = 14)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Afternoon light treatment (1.00-1.30 p.m., n = 15)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Evening light treatment (8.00-8.30 p.m., n = 12)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Morning light treatment followed by evening light (n = 13)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Evening light treatment followed by morning light (n = 14)
Number of subjects: 68
Study: 2371420

Group type: EXPERIMENTAL
Intervention: Chronic obstructive airways disease subjects using an alcolmeter simulator
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy subjects using the roadside alcolmeter at flow rates of 10 l min‐1 and 40 l min‐1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subjects with chronic obstructive airways disease who are drivers or ex-drivers
Number of subjects: 36
Study: 7318359

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg by mouth)
Number of subjects: 6
Study: 31978983

Group type: EXPERIMENTAL
Intervention: Food Addiction Model (FAM) explanation for weight control and obesity
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Diet and exercise explanation
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1220
Study: 30385320

Group type: EXPERIMENTAL
Intervention: Moderate- to high-interfering persistent pain group
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Low perceptual load conditions
Number of subjects: 145

Group type: COMPARATOR
Intervention: Non-chronic pain and low-interfering persistent pain groups
Number of subjects: 145
Study: 29219095

Group type: EXPERIMENTAL
Intervention: Compliance with any individual guideline
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Compliance with any combination of two guidelines
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Compliance with all three guidelines
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Overall compliance with the 24 h movement guidelines
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Physical activity guideline compliance
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sleep guideline compliance
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sedentary behavior guideline compliance
Number of subjects: 202
Study: 25595104

Group type: EXPERIMENTAL
Intervention: Alkalinized solution (lidocaine 1% and epinephrine in sodium bicarbonate 1.4%)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard solution (lidocaine 1% and epinephrine in saline 0.9%)
Number of subjects: 101
Study: 24468092

Group type: EXPERIMENTAL
Intervention: high-frequency repetitive TMS (hf rTMS) (10 Hz) on left DLPFC
Number of subjects: 14

Group type: COMPARATOR
Intervention: sham stimulation (vertex)
Number of subjects: 14
Study: 22748702

Group type: EXPERIMENTAL
Intervention: Apremilast 10 mg twice daily
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice daily
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 19773703

Group type: EXPERIMENTAL
Intervention: At-home palliative care respite service delivered by enrolled nurses
Number of subjects: 0
Study: 17504124

Group type: EXPERIMENTAL
Intervention: Molecular targeted drugs (e.g., Glivec/Imatinib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy drugs
Number of subjects: 0
Study: 17699247

Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg/m2 every other day for 3 months, then 40 mg/m2 every other day for 9 months, then 30 mg/m2 every other day for 12 months
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids 4 g/d for 2 years (1.88 g eicosapentaenoic acid, 1.48 g docosahexaenoic acid)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 14613632

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10100270

Group type: EXPERIMENTAL
Intervention: Ondansetron (5 mg/m2 30 min before chemotherapy, then 4 mg/m2 every 8 h i.v.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tropisetron (0.2 mg/kg 30 min before chemotherapy, max dose 5 mg)
Number of subjects: 23
Study: 8733993

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate 200 micrograms once daily
Number of subjects: 232

Group type: COMPARATOR
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 1853146

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole once daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: 300 mg ranitidine twice daily
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily (maintenance treatment)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 150 mg ranitidine twice daily (maintenance treatment)
Number of subjects: 98
Study: 6853983

Group type: EXPERIMENTAL
Intervention: Routinely sterilized dilators
Number of subjects: 17

Group type: COMPARATOR
Intervention: Resterilized dilators
Number of subjects: 17
Study: 29428426

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy (Pylera)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 14-days sequential therapy
Number of subjects: 60
Study: 26949703

Group type: EXPERIMENTAL
Intervention: BNP (0.005 μg/kg/min before contrast media exposure and saline hydration)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Saline hydration alone (control)
Number of subjects: 209
Study: 25918703

Group type: EXPERIMENTAL
Intervention: COMPLETE RevitaLens
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Synergi
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist
Number of subjects: 31
Study: 23018437

Group type: EXPERIMENTAL
Intervention: AS03A‐adjuvanted H1N1v vaccine (3.75 μg haemagglutinin)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Nonadjuvanted H1N1v vaccine (15 μg haemagglutinin)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: AS03A‐adjuvanted H1N1v vaccine
Number of subjects: 306

Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 306
Study: 21432588

Group type: EXPERIMENTAL
Intervention: High-intensity training condition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-intensity training condition
Number of subjects: 29
Study: 18613246

Group type: EXPERIMENTAL
Intervention: Marginalized random effects models (MREMs) for longitudinal ordinal data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture model for joint distribution of longitudinal measures and progression/death times
Number of subjects: 0
Study: 15884024

Group type: EXPERIMENTAL
Intervention: Guided Participation (GP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 42
Study: 12911461

Group type: EXPERIMENTAL
Intervention: NMDA-antagonist memantine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10579266

Group type: EXPERIMENTAL
Intervention: Acute Respiratory Distress Syndrome (ARDS) patients (n=19)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acute Lung Injury (ALI) patients (n=33)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All patients (n=70)
Number of subjects: 70
Study: 8684799

Group type: EXPERIMENTAL
Intervention: C3F8 gas
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 321

Group type: COMPARATOR
Intervention: Posterior PVR
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Anterior PVR
Number of subjects: 321
Study: 1815879

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 6617715

Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol (0.2 mg/kg)
Number of subjects: 6